Safety evaluation of biopolymer immune implants in rats and rabbits as well as therapeutic effects on gastric cancer peritoneal metastasis carcinoma
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Intraperitoneal and Appendiceal Malignancies · Nanoparticle-Based Drug Delivery · Gastric Cancer Management and Outcomes
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (42)
Show source-provided references
1. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990–2020: Global burden of disease study. Lancet, 1997, 349: 1498–150410.1016/S0140-6736(96)07492-2 ↗
2. Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021. CA Cancer J Clin, 2021, 71: 7–3310.3322/caac.21654 ↗
3. Averbach AM, Jacquet P. Strategies to decrease the incidence of intraabdominal recurrence in resectable gastric cancer. Br J Surg, 1996, 83: 726–73310.1002/bjs.1800830605 ↗
4. Garwood RA, Sawyer MD, Ledesma EJ, et al. A case and review of bowel perforation secondary to metastatic lung cancer. Am Surgeon, 2005, 71: 110–11610.1177/000313480507100204 ↗
5. Kiyokawa T, Young RH, Scully RE. Krukenberg tumors of the ovary. Am J Surg Pathol, 2006, 30: 277–29910.1097/01.pas.0000190787.85024.cb ↗
6. McCluggage WG, Wilkinson N. Metastatic neoplasms involving the ovary: A review with an emphasis on morphological and immunohistochemical features. Histopathology, 2005, 47: 231–24710.1111/j.1365-2559.2005.02194.x ↗
7. Rynne-Vidal A, Jiménez-Heffernan J, Fernández-Chacón C, et al. The mesothelial origin of carcinoma associated-fibroblasts in peritoneal metastasis. Cancers, 2015, 7: 1994–201110.3390/cancers7040872 ↗
8. Chua TC, Yan TD, Saxena A, et al. Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure? Ann Surg, 2009, 249: 900–90710.1097/SLA.0b013e3181a45d86 ↗
9. Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: Evolution of management in the era of precision medicine. CA Cancer J Clin, 2019, 69: 280–30410.3322/caac.21559 ↗
10. Orditura M. Treatment of gastric cancer. World J Gastroenterol, 2014, 20: 1635–164910.3748/wjg.v20.i7.1635 ↗
11. Sugarbaker PH. New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol, 2006, 7: 69–7610.1016/S1470-2045(05)70539-8 ↗
12. Weitz J, Koch M, Debus J, et al. Colorectal cancer. Lancet, 2005, 365: 153–16510.1016/S0140-6736(05)17706-X ↗
13. Jin Q, Liu Z, Chen Q. Controlled release of immunotherapeutics for enhanced cancer immunotherapy after local delivery. J Control Release, 2021, 329: 882–89310.1016/j.jconrel.2020.10.019 ↗
14. Yang C, Blum NT, Lin J, et al. Biomaterial scaffold-based local drug delivery systems for cancer immunotherapy. Sci Bull, 2020, 65: 1489–150410.1016/j.scib.2020.04.012 ↗
15. Chen Q, Wang C, Zhang X, et al. In situ sprayed bioresponsive immunotherapeutic gel for post-surgical cancer treatment. Nat Nanotech, 2019, 14: 89–9710.1038/s41565-018-0319-4 ↗
16. Bhattarai N, Gunn J, Zhang M. Chitosan-based hydrogels for controlled, localized drug delivery. Adv Drug Deliver Rev, 2010, 62: 83–9910.1016/j.addr.2009.07.019 ↗
17. Ding SY, Yi J, Li JF, et al. Nanostructure-based plasmon-enhanced Raman spectroscopy for surface analysis of materials. Nat Rev Mater, 2016, 1: 1602110.1038/natrevmats.2016.21 ↗
18. Wang H, Heilshorn SC. Adaptable hydrogel networks with reversible linkages for tissue engineering. Adv Mater, 2015, 27: 3717–373610.1002/adma.201501558 ↗
19. Zhao F, Ma ML, Xu B. Molecular hydrogels of therapeutic agents. Chem Soc Rev, 2009, 38: 883–89110.1039/b806410p ↗
20. Chao Y, Liang C, Tao H, et al. Localized cocktail chemoimmunotherapy after in situ gelation to trigger robust systemic antitumor immune responses. Sci Adv, 2020, 6: eaaz420410.1126/sciadv.aaz4204 ↗
21. Padmakumar S, Paul-Prasanth B, Pavithran K, et al. Long-term drug delivery using implantable electrospun woven polymeric nanotextiles. Nanomed-Nanotechnol Biol Med, 2019, 15: 274–28410.1016/j.nano.2018.10.002 ↗
22. Si X, Ji G, Ma S, et al. In-situ-sprayed dual-functional immunotherapeutic gel for colorectal cancer postsurgical treatment. Adv Healthcare Mater, 2021, 10: e210086210.1002/adhm.202100862 ↗
23. Xu Y, Ma S, Zhao J, et al. Trinity immune enhancing nanoparticles for boosting antitumor immune responses of immunogenic chemotherapy. Nano Res, 2022, 15: 1183–119210.1007/s12274-021-3622-6 ↗
24. Yu Z, Xu Y, Yao H, et al. A simple and general strategy for postsurgical personalized cancer vaccine therapy based on an injectable dynamic covalent hydrogel. BioMater Sci, 2021, 9: 6879–688810.1039/D1BM01000J ↗
25. Ji G, Ma L, Yao H, et al. Precise delivery of obeticholic acid via nanoapproach for triggering natural killer T cell-mediated liver cancer immunotherapy. Acta Pharmaceutica Sin B, 2020, 10: 2171–218210.1016/j.apsb.2020.09.004 ↗
26. Si X, Song W, Yang S, et al. Glucose and pH dual-responsive nanogels for efficient protein delivery. MacroMol Biosci, 2019, 19: 190014810.1002/mabi.201900148 ↗
27. Thambi T, Li Y, Lee DS. Injectable hydrogels for sustained release of therapeutic agents. J Control Release, 2017, 267: 57–6610.1016/j.jconrel.2017.08.006 ↗
28. Singh NK, Nguyen QV, Kim BS, et al. Nanostructure controlled sustained delivery of human growth hormone using injectable, biodegradable, pH/temperature responsive nanobiohybrid hydrogel. Nanoscale, 2015, 7: 3043–305410.1039/C4NR05897F ↗
29. Kim DH, Seo YK, Thambi T, et al. Enhancing neurogenesis and angiogenesis with target delivery of stromal cell derived factor-1α using a dual ionic pH-sensitive copolymer. Biomaterials, 2015, 61: 115–12510.1016/j.biomaterials.2015.05.025 ↗
30. Ji G, Zhang Y, Si X, et al. Biopolymer immune implants’ sequential activation of innate and adaptive immunity for colorectal cancer postoperative immunotherapy. Adv Mater, 2021, 33: e200455910.1002/adma.202004559 ↗
31. Si X, Ji G, Ma S, et al. Comprehensive evaluation of biopolymer immune implants for peritoneal metastasis carcinoma therapy. J Control Release, 2023, 353: 289–30210.1016/j.jconrel.2022.11.028 ↗
32. Ma S, Song W, Xu Y, et al. Rationally designed polymer conjugate for tumor-specific amplification of oxidative stress and boosting antitumor immunity. Nano Lett, 2020, 20: 2514–252110.1021/acs.nanolett.9b05265 ↗
33. Laidlaw BJ, Zhang N, Marshall HD, et al. CD4+ T cell help guides formation of CD103+ lung-resident memory CD8+ T cells during influenza viral infection. Immunity, 2014, 41: 633–64510.1016/j.immuni.2014.09.007 ↗
34. André T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med, 2004, 350: 2343–235110.1056/NEJMoa032709 ↗
35. Song W, Shen L, Wang Y, et al. Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap. Nat Commun, 2018, 9: 223710.1038/s41467-018-04605-x ↗
36. Hemmi H, Kaisho T, Takeuchi O, et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol, 2002, 3: 196–20010.1038/ni758 ↗
37. Jurk M, Heil F, Vollmer J, et al. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat Immunol, 2002, 3: 49910.1038/ni0602-499 ↗
38. Kanneganti TD, Özören N, Body-Malapel M, et al. Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3. Nature, 2006, 440: 233–23610.1038/nature04517 ↗
39. Liu T, Si X, Liu L, et al. Injectable nano-in-gel vaccine for spatial and temporal control of vaccine kinetics and breast cancer postsurgical therapy. ACS Nano, 2024, 18: 3087–310010.1021/acsnano.3c08376 ↗
40. Si X, Song W, Chen X. Injectable nano-in-gel vaccine for spatial and temporal control of vaccine kinetics and breast cancer postsurgical therapy. Acta Polym Sin, 2023, 54: 837–852
41. Xu Y, Ma S, Zhao J, et al. Polymeric drug delivery materials for cancer immunotherapy. Biomaterials, 2022, 284: 12148910.1016/j.biomaterials.2022.121489 ↗
42. Zhao J, Xu Y, Ma S, et al. A minimalist binary vaccine carrier for personalized postoperative cancer vaccine therapy. Adv Mater, 2022, 34: 210925410.1002/adma.202109254 ↗